Flow Cytometry – Products

Sphere Fluidics announced Biosyntia, a biotechnology company focused on synthetic biology and metabolic engineering, has adopted the Pico-Mine® platform within its workflows.

Pixelgen Technologies®, announced the commercial launch of its first kit, based on the company's proprietary Molecular Pixelation (MPX) technology for spatial analyses of immune cell surface proteins in 3D.

Deepcell has announced the launch of the REM-I Platform, a high-dimensional cell morphology analysis and sorting platform which comprises the REM-I benchtop instrument, Human Foundation Model and Axon data suite.

Beckman Coulter Life Sciences is helping laboratories prepare for critical upgrades to comply with the new In Vitro Diagnostic Medical Devices Regulation (IVDR), and clearing up confusion for laboratories that will soon be governed by IVDR.

The Skeletal Muscle Differentiation kit from AMSBIO provides a unique protocol to differentiate human pluripotent stem cells to skeletal muscle with high yields and without cell sorting or genetic manipulation.

Evergreen Discovery and Orbit Discovery Ltd have announced that they have entered into a collaboration to identify specific cell targeting peptides and advance the development of novel radiopharmaceuticals.

A new study has shown graphene-based biosensors could play a major role in detecting Interleukin-10 (IL-10), an important inflammation regulator, at significantly lower levels than previous point-of-care measurements.

Recent technological advancements have made single-cell multi omics (genomics, proteomics, metabolomics) an increasingly powerful tool for diagnosis, treatment response prediction and treatment selection for cancer. The process begins with disaggregation of a fresh or frozen sample into a single-cell suspension, followed by preparation of a single-cell next-generation sequencing (NGS) library, then data analysis. Find out more...

TransCure bioServices has developed cell line-derived xenograft mouse models that will change how researchers tackle the preclinical studies of cancer therapies to treat acute myeloid leukemia.

Antiverse Ltd has announced the successful identification of functional antibody clusters targeting two G-protein-coupled receptors, both displaying versatile binding profiles and nanomolar affinity.